Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Tetravalent dengue vaccine development].

Virologie (Montrouge, France)·2022
Same author

Combine two different dengue vaccines could efficiently target dengue-naive subjects. Comment to Macias A, Ruiz-Palacios G, Ramos-Castaneda J. Combine dengue vaccines to optimize effectiveness. Vaccine. 2020 Jun 26;38(31):4801-4804.

Vaccine·2020
Same author

When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?

Vaccines·2020
Same author

Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.

Journal of travel medicine·2019
Same author

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

PloS one·2019
Same author

Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses.

Vaccine·2019

Related Experiment Video

Updated: Jul 14, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

The perfect mix: recent progress in adjuvant research.

Bruno Guy1

  • 1Research Department, sanofi pasteur, Campus Merieux, 69280 Marcy l'Etoile, France. bruno.guy@sanofipasteur.com

Nature Reviews. Microbiology
|June 15, 2007
PubMed
Summary

Developing new vaccine adjuvants is crucial for effective immunization. Advances in immunology and biochemistry enable the creation of tailored immunostimulants for specific vaccine targets and desired immune responses.

Area of Science:

  • Immunology
  • Vaccinology
  • Biochemistry

Background:

  • Traditional vaccine adjuvants, like aluminum salts, are often empirically chosen and may not induce robust cell-mediated immunity.
  • New vaccine targets necessitate the development of novel immunostimulants capable of eliciting specific adaptive immune responses.

Purpose of the Study:

  • To review recent advances in adjuvant research for human vaccines.
  • To highlight the shift towards rationally designed adjuvants based on innate immune signaling.

Main Methods:

  • Discussion of research elucidating innate immune signals that shape adaptive immunity.
  • Review of biochemical techniques enabling the design of targeted immunostimulants.

Main Results:

More Related Videos

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jul 14, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

  • A growing panel of specific and focused adjuvants is now available for vaccine development.
  • Adjuvants can be combined synergistically to create tailored formulations.

Conclusions:

  • Vaccinologists can now select and combine adjuvants to optimize vaccine efficacy for specific targets.
  • Formulations can be adapted to induce desired immune responses and correlate with protection.